Company profile
Immedica Pharma AB
Privately held: no public share price (Stockholm-based rare-disease specialty pharma, privately owned via a joint acquisition by private-equity firms KKR and Impilo (completed September 2024); not publicly listed. Sources: https://clinicaltrials.gov/study/NCT05249556 ; https://api.gleif.org/api/v1/lei-records/549300Q0QKHL3MF7FV02 ; https://impilo.se/news/kkr-and-impilo-announce-strategic-partnership-together-with-management-in-rare-disease-platform-immedica-pharma/ ; https://www.immedica.com/en/about-us Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | GABA-A receptorSmall molecule | Epilepsy |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.